Phaseline

Companies › Eli Radiopharma

Eli Radiopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[18F]Flortaucipir Injection
Tau neurofibrillary tangle (NFT) PET imaging agent - binds to aggregated tau protein
MAPTPhase 1AD - Alzheimer's DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07580703[18F]Flortaucipir InjectionPhase 1AD - Alzheimer's DiseaseNeurologyDec 2026

Targets

MAPT (1)

Companies with the same targets

Bristol-Myers Squibb Roche Voyager Therapeutics Amyloid Solution Arrowhead Pharmaceuticals Nuravax Oligomerix UCB Biopharma SRL

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.